C diff: September's Review in Research and News

Advocating for Better Regulatory Rules and Standard of Care for C difficile

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.

Investigational Antibiotic for C difficile Meets Primary Endpoint

Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Investigational C Diff Therapy Shows Favorable Microbiome Characteristics, Phase 3 Trial Planned

he latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.

Assessing the Relationship Between C-diff Risk and Antibiotic Exposure
C diff remains a major healthcare burden globally, with over 225,000 hospitalizations in the US alone. Over half of these cases had recent antibiotic exposure, underlining the significant relationship between antibiotic use and the risk of the healthcare-associated infection.

Uncovering C difficile Transmission in Hospitals through Whole-Genome Sequencing

By analyzing 38 strains from patients, researchers identified clusters linked to frequent room changes, highlighting the need for improved infection control measures.